Myositis ossificans progressiva, hand and finger(s)
ICD-10 M61.14 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, hand and finger(s).
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles, tendons, and other connective tissues. This condition typically begins in early childhood and progresses over time, leading to significant muscle weakness and restricted mobility. In cases where the hand and fingers are affected, patients may experience stiffness, pain, and a gradual loss of function due to the ossification of soft tissues. The condition is caused by mutations in the ACVR1 gene, which plays a crucial role in bone growth and development. Diagnosis is often made through clinical evaluation, imaging studies, and genetic testing. Management focuses on symptomatic relief, physical therapy, and avoiding trauma to affected areas, as injuries can exacerbate ossification. Understanding the implications of MOP is essential for healthcare providers, as it impacts the patient's quality of life and requires a multidisciplinary approach for optimal care.
Detailed clinical notes on muscle strength, range of motion, and any imaging studies performed.
Patients presenting with progressive muscle stiffness and pain in the hands and fingers.
Ensure that all relevant genetic testing and imaging results are included in the documentation.
Comprehensive family history and genetic test results to confirm diagnosis.
Patients with a family history of myositis ossificans or unexplained ossification.
Documentation should clearly outline the genetic basis of the condition and any counseling provided.
Used for initial assessment of muscle function and mobility in patients with MOP.
Detailed evaluation notes including range of motion and strength testing.
Physical therapists should document specific limitations due to ossification.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues, leading to progressive disability.
Diagnosis is made through clinical evaluation, imaging studies, and genetic testing to confirm mutations in the ACVR1 gene.
